

Press Release

Astellas announces the intended decision to transfer its manufacturing plant and business based in Meppel, the Netherlands, to Delpharm

TOKYO, May 25, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that Astellas B.V. and Astellas Pharma Europe B.V., Astellas’ subsidiaries in Netherlands, have made an intended decision to sell and transfer its manufacturing plant, located in Meppel, the Netherlands (the “Business”), to Delpharm Industrie SAS (CEO: Sébastien Aguetant, “Delpharm”). The definitive agreement will be executed after completing works council consultation and local legal and regulatory requirements.

1. Summary of the intended transaction

(1) Purpose rationale

Astellas is committed to the process of optimizing resources to adapt and successfully perform in a rapidly changing business environment. This includes the areas of technology and manufacturing in which Astellas actively strengthens its capabilities and develops ties with partners to promote a stable supply of high-quality medicines. As part of these efforts, Astellas B.V. and Astellas Pharma Europe B.V. have made the intended decision to sell and transfer the Business to Delpharm.

Upon the transfer of the Business to Delpharm, the plan is that Delpharm will continue to manufacture the products that are currently manufactured at the plant in Meppel and will deliver these products to Astellas group to ensure the stable supply of products for patients. This collaboration between Delpharm and Astellas will allow Astellas to utilize a high-quality and efficient outsourced manufacturing system in Meppel. As part of the sale and transfer of the Business, the employees will also transfer to Delpharm.

(2) Schedule

- May 24, 2023: Intended decision is made by Astellas
- Second quarter of Astellas’ fiscal year 2023: Signing of a definitive agreement (tentative) subject to works council consultation.

- Fourth quarter of Astellas' fiscal year 2023: Completion of transfer to Delpharm (tentative).

(3) Financial terms

Financial terms of the transaction, including the purchase price, are not disclosed.

2. Outline of the relevant parties

■ Astellas B.V

Headquarters: Leiden, The Netherlands

Representative: Stef Schutte

Capital: € 6.12 million

Operations: Financial Holding

Employees: 11 (as of May 2023)

Production sites: none

■ Astellas Pharma Europe B.V.

Headquarters: Leiden, The Netherlands

Representative: Stef Schutte

Capital: € 33.75 million

Operations: Technology & Manufacturing, Medical & Development, Commercial, Supporting Functions

Employees: 346 (as of May 2023)

Production sites: Meppel Plant

■ The Meppel Plant

Location: Hogemaat 2, 7942 JG Meppel, the Netherlands

Site area: 46,337 m²

Building area: 21,000 m²

Employees: 332 employees (as of May 2023)

Forms of pharmaceuticals being produced: tablets, capsules, and granule medicines

Production Results: approx. 1.3 billion tablets, approx. 50 million packs, and approx. 80 tons granules (as of the end of March 2023)

■ Delpharm Industrie SAS

Headquarters: Boulogne-Billancourt, France

Representative: CEO Sébastien Aguetant

Sales: €1 billion

Operations: manufacturing sites located across Europe

Employees: approx. 6,500 employees (as of the end of March 2023)

The impact of this transaction on Astellas' financial results for the fiscal year ending March 31, 2024, is expected to be minor.

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new medicines to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+[®] healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at <https://www.astellas.com/en>.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Advocacy & Relations
+81-3-3244-3201